About Halozyme Therapeutics (HALO)

The current price per share for Halozyme Therapeutics (HALO) is $56.23. The stock has seen a price change of $0.26 recently, indicating a 0.46% change. This reflects the stock's recent market performance and investor sentiment.

For Halozyme Therapeutics (HALO), the 52-week high is $57.05, which is 1.45% from the current price. The 52-week low is $32.83, the current price is 71.28% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

Halozyme Therapeutics (HALO) has shown an average price growth of 0.41% over the past three years. It has received a score of 43 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Halozyme Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, Halozyme Therapeutics (HALO) has a year-to-date price change of 50.39%. Over the past month, the stock has experienced a price change of 7.31%. Over the last three months, the change has been 46.2%. Over the past six months, the figure is 62.94%. Looking at a longer horizon, the five-year price change stands at 240.17%.

Halozyme Therapeutics (HALO) has a net income of $281.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 76.8% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 48.78% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $829.25M, with a revenue growth rate of 25.62%, providing insight into the company's sales performance and growth. The gross profit is $636.89M. Operating income is noted at $337.57M. Furthermore, the EBITDA is $463.92M.

Halozyme Therapeutics (HALO) has a market capitalization of $7.14B. The average daily trading volume is 1.16M, indicating the stock's liquidity and investor engagement.